%0 Journal Article
%T Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
%A Akinari Sekine
%A Eiko Hasegawa
%A Hiroki Mizuno
%A Junichi Hoshino
%A Keiichi Sumida
%A Kenichi Ohashi
%A Kenmei Takaichi
%A Masahiro Kawada
%A Masayuki Yamanouchi
%A Naoki Sawa
%A Naoya Toriu
%A Noriko Hayami
%A Rikako Hiramatsu
%A Shuichiro Matoba
%A Takeshi Fujii
%A Tatsuya Suwabe
%A Yoshifumi Ubara
%J Archive of "Case Reports in Oncology".
%D 2019
%R 10.1159/000500716
%X An 88-year-old Japanese man received bevacizumab for colorectal cancer with liver and peritoneal metastasis, during which nephrotic range proteinuria occurred (7.66 g/day). Renal biopsy showed endothelial damage with subendothelial swelling and a double contour of the glomerular basement membrane, which indicated a diagnosis of thrombotic microangiopathy (TMA). After bevacizumab was stopped, proteinuria decreased to 1 g/day. During the clinical course, this patient had no extrarenal manifestations. This case suggests that renal injury induced by bevacizumab is characterized by nephrotic range proteinuria and histological TMA, and is a renal-limited condition that differs from systemic TMA related to thrombotic thrombocytopenic purpura
%K Thrombotic microangiopathy
%K Bevacizumab
%K Nephrotic syndrome
%K Colorectal cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587198/